Bellus Health: BELLUS Health- developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. BELLUS' lead product candidate, BLU-5937, is being developed for the treatment of chronic cough (Phase II announced July 2020) and chronic pruritus (Phase II planned to begin 1H20).

BELLUS' Phase II for chronic cough, the RELIEF study is a dose-escalation, placebo-controlled, and crossover design to assess the efficacy, safety, and tolerability of BLU-5937, a highly selective P2X3 antagonist, at four doses; 25, 50, 100 and 200 mg, administered orally, twice-daily (BID). Approximately 65 patients with refractory chronic cough are expected to be enrolled at twelve clinical sites in the United Kingdom and United States.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Canada
Clinical Stage
Phase l or ll
Disease Space
Respiratory
Industry
Biotechnology
Listing
Public, ROW
Market Cap
100MM - 500MM
Therapeutic Modalities
Small Molecule
Website:
Profiles:
Address:
275 Armand-Frappier Boulevard
Laval, Quebec H7V 4A7
Canada

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.